SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company developing human immunoglobulin G (hIgG) therapies for immune and autoimmune disorders. Its platform uses transchromosomic bovine technology to generate disease-targeted polyclonal antibodies, with lead development centered on SAB-142 for autoimmune type 1 diabetes.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueSAB-142 and related development programs targeting autoimmune type 1 diabetes.
Other hIgG product candidates for immune and autoimmune disorders.
Proprietary transchromosomic cattle platform used to produce disease-targeted hIgG.
Research and development supported by U.S. government programs and contracts.
Customers
SAB Biotherapeutics primarily serves government agencies, clinical investigators, and future commercial patients through its development programs rather than selling established products today. Its near-term counterparties are research collaborators, regulators, contract providers, and funding agencies that support clinical development and platform advancement. If approved, its therapies would be directed to patients with autoimmune and immune-mediated diseases, especially type 1 diabetes.
U.S. agencies and programs that fund development, countermeasure, and rapid-response work.
Trial sites, investigators, CROs, and collaborators supporting SAB-142 and other studies.
Patients with type 1 diabetes and other autoimmune disorders who would use approved therapies.
Potential partners for sales, marketing, and distribution if products reach approval.
Strategy
SAB Biotherapeutics is focused on advancing its lead hIgG programs through clinical development and building the evidence needed for regulatory approval. It is also expanding its Tc-Bovine production capacity and seeking to preserve optionality for future commercialization through partnerships or an internal sales capability. The platform strategy emphasizes differentiated, polyclonal antibody biology that can be applied to multiple immune and autoimmune indications.
The lead candidate is the main value driver and proof point for the platform.
A broader indication set can increase the addressable market for the hIgG platform.
Animal-based plasma production requires capacity, redundancy, and operational control.
Approval alone is not sufficient without sales, marketing, and distribution execution.
Geography
The company is headquartered in the United States and conducts its core development and corporate activities from there. Its regulatory and development pathway also references the FDA, the UK MHRA, and Australia’s TGA, indicating a multi-jurisdiction development footprint. Operationally, its animal-based production platform depends on dedicated specialty facilities, including a planned redundant facility at a separate location.
Risks
The company faces the typical risks of a clinical-stage biotech: clinical failure, regulatory delay, and the need for substantial external capital before commercialization. Its platform also depends on specialized animal facilities, third-party collaborators, and data integrity across the development chain, which can create operational and regulatory exposure. Because it has no established product revenue base, financing and execution risk remain central to the business model.
- Financing and going-concern riskImpact: CriticalLikelihood: High
The company expects continued losses and needs external capital to operate.
Exposure: Corporate continuity and pipeline funding
- Clinical development failureImpact: HighLikelihood: High
The company depends on proving SAB-142 and other candidates in human studies.
Exposure: Lead candidate and pipeline value
- Regulatory approval riskImpact: HighLikelihood: High
Product candidates must satisfy FDA and other regulators before commercialization.
Exposure: SAB-142 and future autoimmune indications
- Manufacturing and facility dependenceImpact: MediumLikelihood: Medium
Tc-Bovine plasma production requires specialized animal facilities and redundancy.
Exposure: Supply continuity and scale-up
- Third-party collaboration and data integrity riskImpact: MediumLikelihood: Medium
R&D and clinical work rely on CROs, contractors, and external scientific data.
Exposure: Trial execution and decision-making
Accounting
Judgemental itemsRevenue has come from grants and contract closeout activity, making timing and classification important.
Impact: Affects reported revenue and comparability across periods
Trial costs, CRO invoices, and vendor services require estimates before cash settlement.
Impact: Affects operating expense timing
Loss history makes realizability of tax assets uncertain.
Impact: Affects tax provision and equity
Cash runway and future financing assumptions are central to financial statement presentation.
Impact: Affects liquidity disclosure and investor interpretation
Similar listed companies
Publicly listed companies with a comparable business focus.
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Sana Biotechnology, Inc.
SANA · Biological Products, (No Diagnostic Substances)
Veru Inc
VERU · Pharmaceutical Preparations
Jade Biosciences, Inc.
JBIO · Pharmaceutical Preparations
Atara Biotherapeutics, Inc.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
CASI Pharmaceuticals, Inc.
CASIF · Pharmaceutical Preparations
Last updated: 24/09/2026